<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cyclic vomiting syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cyclic vomiting syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cyclic vomiting syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">B UK Li, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicholas J Talley, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melvin B Heyman, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cyclic vomiting syndrome (CVS) is an idiopathic disorder characterized by recurrent, stereotypical bouts of vomiting with intervening periods of normal or baseline health [<a href="#rid1">1</a>]. Both children and adults are affected, although the clinical presentation and natural history vary somewhat with age [<a href="#rid2">2-6</a>].</p><p>CVS was first described in the late 1800s [<a href="#rid7">7,8</a>]. The key features are [<a href="#rid9">9,10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent discrete episodes of vomiting</p><p class="bulletIndent1"><span class="glyph">●</span>Varying intervals of normal (or baseline) health between episodes</p><p class="bulletIndent1"><span class="glyph">●</span>Episodes are stereotypical with regard to timing of onset, symptoms, and duration</p><p class="bulletIndent1"><span class="glyph">●</span>The vomiting is not attributable to other disorders</p><p></p><p>This topic review will provide an overview of CVS in children and adults. Treatment guidelines have been published for children [<a href="#rid9">9</a>] and adults [<a href="#rid10">10</a>]. Overviews of other causes of vomiting are presented separately. (See  <a class="medical medical_review" href="/d/html/5902.html" rel="external">"Approach to the infant or child with nausea and vomiting"</a> and  <a class="medical medical_review" href="/d/html/2537.html" rel="external">"Approach to the adult with nausea and vomiting"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>CVS is no longer considered to be rare in children or adults.</p><p>The prevalence of CVS in children is estimated at 1.9 to 2.3 percent, with an incidence of 3.2 per 100,000 population, based on studies in predominantly White populations [<a href="#rid11">11-13</a>]. The average age was 9.6 years at the time of diagnosis, while the average age at the onset of symptoms was 5.3 years. CVS appears to be more common in girls than boys, with a ratio of 55:45 [<a href="#rid1">1,9,14-18</a>]. CVS is highly associated with a history of migraines, either in the patient or (especially in children) a maternal family member (72 to 82 percent) [<a href="#rid19">19</a>]. A family in which CVS appears to be inherited has been described [<a href="#rid20">20</a>].</p><p>The prevalence of CVS in adults appears to be slightly lower than that in children. In a multinational survey of functional disorders conducted in 33 countries, the overall prevalence was 1.2 percent, equal across sex with similar proportions in males and females and higher (1.6 percent) in younger adults ages 18 to 39 years compared with older adults [<a href="#rid21">21</a>]. CVS represented 10.8 percent of functional gastrointestinal disorders seen in an adult gastroenterology clinic and 2 percent in a population survey of English-speaking patients [<a href="#rid22">22,23</a>]. In one of the largest studies of 101 adults, patients could be divided into subgroups with pediatric-onset or adult-onset of CVS, in which symptoms began at a mean age of 13 versus 32 years, respectively [<a href="#rid2">2,24</a>]. These groups differed significantly in sex predominance (86 percent female in pediatric-onset versus 57 percent female in adult-onset disease). Another study found that the CVS began at an average age of 35 (range 14 to 73 years) but was not diagnosed until patients were on average 41 years old [<a href="#rid25">25</a>]. Compared with children, adults with CVS tend to have less frequent episodes but with far longer duration. (See <a class="local">'Adults'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of CVS remains unknown; however, it appears to be multifactorial, with several potential pathways. An association between CVS and migraine headaches has been most consistently described in children and adults, suggesting that there may be a common pathophysiologic process. However, CVS has also been linked to autonomic abnormalities (elevated sympathetic tone and impaired parasympathetic regulation), hypothalamic-pituitary-adrenal activation (Sato variant), mitochondrial dysfunction, menses (estrogen sensitivity), food allergy, and cannabis use [<a href="#rid1">1,26</a>]. One review notes that chronic migraine, epilepsy, panic disorder, and CVS have similar temporal patterns and triggers and posits a neuroexcitability threshold, which when exceeded (due to enhanced susceptibility plus acute stressors), triggers episodic attacks of vomiting [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Association with migraines</span><span class="headingEndMark"> — </span>CVS has been linked to migraine headaches and abdominal migraine  (<a class="graphic graphic_table graphicRef80667" href="/d/graphic/80667.html" rel="external">table 1</a>) [<a href="#rid27">27,28</a>]. This association is based upon the discreteness of episodes, the progression from cyclic vomiting to migraine headaches in many patients, the presence of a strong family history of migraine headaches in affected children (approximately 80 percent), and the response to antimigraine therapy in up to 80 percent of children [<a href="#rid9">9,19</a>]. In adults, CVS is also associated with a personal history (43 percent) or family history (64 percent) of migraines and often responds to antimigraine therapy [<a href="#rid2">2</a>]. Underlying autonomic sympathetic and parasympathetic dysfunction may predispose children and adults to both CVS and migraine headaches [<a href="#rid24">24,29,30</a>]. (See  <a class="medical medical_review" href="/d/html/6161.html" rel="external">"Pathophysiology, clinical features, and diagnosis of migraine in children"</a>.)</p><p>Cross-sectional prevalence data suggest that CVS (which predominates at a mean age of five years) often progresses to abdominal migraines (mean age nine years), which in turn lead to migraine headaches (mean age 11 years) [<a href="#rid11">11</a>]. However, many children progress directly from CVS to migraines. (See <a class="local">'Natural history'</a> below.)</p><p class="headingAnchor" id="H1557580284"><span class="h2">Mitochondrial dysfunction</span><span class="headingEndMark"> — </span>Mitochondrial disorders of fatty acid oxidation (eg, medium-chain acyl-coenzyme A dehydrogenase deficiency), respiratory chain defects (eg, MELAS [mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes]), and mitochondrial DNA deletions can be associated with episodes of metabolic crisis and vomiting, usually triggered by infection or prolonged fasting [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/2936.html" rel="external">"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features"</a> and  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis"</a>.)</p><p>The hypothesis that mitochondrial dysfunction contributes to CVS in some patients is suggested by findings of maternal inheritance of two common mitochondrial DNA polymorphisms, 16519T and 3010A, reported in approximately one-half of White children with CVS with haplotype H [<a href="#rid32">32,33</a>]. This association appears to be common in children but not in adults. Further support comes from clinical observations of the efficacy of mitochondrial-targeted therapies, coenzyme Q10 [<a href="#rid34">34,35</a>] and L-carnitine [<a href="#rid34">34-36</a>], in CVS. This hypothesis is further strengthened by an association of both CVS and migraine headache with the same two mitochondrial DNA polymorphisms [<a href="#rid37">37</a>]. Sequencing of nuclear DNA suggests that there may be synergistic polymorphisms in some genes (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F180902&amp;token=87jLzclRwWxNoI%2BQq5Gg77Fyn80mCj%2Fk6HhD243jZaIuYTvhRbBEGoF2FdXF19FL&amp;TOPIC_ID=2588" target="_blank"><i>RYR2</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F603967&amp;token=87jLzclRwWxNoI%2BQq5Gg787mVMWwDKy5oGRIH8rJSywY9BE9scOtk0lVW1Ol4aF%2F&amp;TOPIC_ID=2588" target="_blank"><i>SCN4A</i></a>) that impact cellular stress responses in CVS [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Autonomic dysfunction</span><span class="headingEndMark"> — </span>Children and adults with CVS have been found to have augmented sympathetic tone with low to normal parasympathetic tone [<a href="#rid24">24,29</a>]. In one small series, 47 percent of affected adolescents were found to meet criteria for postural orthostatic tachycardia syndrome (POTS) and treatment of that comorbid condition helped prevent episodes of vomiting [<a href="#rid30">30,39</a>]. In two small series of adult patients, 23 to 35 percent had postural tachycardia or orthostatic hypotension [<a href="#rid40">40,41</a>]. Patients who have a hereditary sensory autonomic neuropathy (such as Riley-Day syndrome) sometimes have clinical episodes resembling CVS. (See  <a class="medical medical_review" href="/d/html/6227.html" rel="external">"Hereditary sensory and autonomic neuropathies"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Hypothalamic-pituitary-adrenal axis hyperreactivity</span><span class="headingEndMark"> — </span>A subset of children with CVS have prolonged and severe episodes, associated with profound lethargy and intra-episodic hypertension, known as the Sato variant [<a href="#rid42">42</a>]. These children also have intra-episodic elevations of corticotropin, cortisol, vasopressin, prostaglandin E2, and catecholamines, suggesting hypothalamic-pituitary-adrenal axis hyperreactivity. Animal studies suggest that CVS may be a brain-gut disorder in which corticotropin-releasing factor triggers gastric stasis and vomiting by vagal stimulation [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H126446690"><span class="h2">Association with rapid gastric emptying or gastroparesis</span><span class="headingEndMark"> — </span>In adults, gastric emptying may be accelerated or sometimes delayed in CVS, but any association with symptoms is controversial. One hypothesis is that rapid gastric emptying is a marker for underlying dysautonomia [<a href="#rid24">24,44</a>]. Paradoxically, there may be an overlap between CVS and idiopathic gastroparesis in adults. Testing of gastric emptying to exclude gastroparesis may be considered if cyclic vomiting symptoms are refractory to therapy [<a href="#rid44">44,45</a>] (see <a class="local">'Adults'</a> below). Gastric emptying is generally normal in children with CVS [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H1429156916"><span class="h2">Estrogen sensitivity (catamenial cyclic vomiting syndrome)</span><span class="headingEndMark"> — </span>Similar to menstrual migraine headaches, some adolescent girls (22 percent) develop CVS at the onset of their menstrual periods (catamenial CVS). This phenomenon is postulated to be the result of the premenstrual decline in estrogen, and many patients with this pattern respond to treatment with low-dose estrogen, progesterone-only oral contraceptives, or a <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> intramuscular injection every three months. An association between CVS and menses has also been described in adults [<a href="#rid25">25</a>]. (See <a class="local">'Catamenial cyclic vomiting syndrome'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h2">Chronic cannabis use</span><span class="headingEndMark"> — </span>Cannabis hyperemesis syndrome (CHS) is characterized by episodic vomiting associated with prolonged, high-dose (nearly daily) recreational cannabis use and that resolves with cannabis cessation [<a href="#rid5">5,47</a>]. This disorder primarily affects young adult and adolescent males, as described in growing numbers of case series [<a href="#rid23">23,48-54</a>]. Among people with cannabis use disorder, almost one-half experience withdrawal symptoms when tapering use [<a href="#rid55">55</a>].</p><p>Circumstantial evidence suggests that CHS is a subset of CVS that is triggered by <strong>chronic</strong> (eg, &gt;2 years), <strong>frequent</strong> (eg, ≥4 times/week), high-dose cannabis use, although it can be difficult to distinguish between these disorders [<a href="#rid10">10,54,55</a>]. Both CHS and CVS are associated with characteristic, repetitive hot-water bathing behavior, which is seen during cannabis-associated vomiting cycles [<a href="#rid47">47,51</a>] as well as in typical CVS attacks in both adults (48 percent) and children who have not been exposed to cannabis [<a href="#rid56">56</a>]. However, reverse causality is also possible since many adults with CVS self-medicate with cannabis to alleviate their daily nausea, and this can be a source of diagnostic confusion. Patients with classic CVS symptoms and modest, intermittent therapeutic use of cannabis are frequently mislabeled as having CHS.</p><p>For patients with CVS-like symptoms who have a history of chronic frequent cannabis use, we suggest a trial of prolonged abstinence from cannabis. The duration of cannabis cessation needed to exclude a diagnosis of CHS is not well defined in the literature. A report from experts in CVS suggests that symptom resolution with cannabis abstinence for six months or three typical CVS cycles is needed for diagnosis of CHS. A presumptive diagnosis of CHS can also be made for patients unable to abstain from cannabis products [<a href="#rid54">54</a>]. Of note, patients who do not experience long-term resolution of symptoms following prolonged abstention from cannabis should be diagnosed with CVS rather than CHS. If emetic episodes persist despite abstention from cannabis, then further work-up for CVS should be undertaken and corresponding treatment trialed. (See  <a class="medical medical_review" href="/d/html/141176.html" rel="external">"Cannabinoid hyperemesis syndrome"</a>.)</p><p class="headingAnchor" id="H1152947956"><span class="h2">Food sensitivity</span><span class="headingEndMark"> — </span>Foods that trigger CVS in some patients include chocolate, cheese, and monosodium glutamate, similar to the triggers that have been reported for migraines. However, the commonly-held association with dietary triggers has been called into question in blinded provocative trials [<a href="#rid57">57</a>]. If a causal association has not been established, we suggest a trial of avoidance only if the clinical history suggests that a food is a trigger for an individual patient (see  <a class="medical medical_review" href="/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Precipitating and exacerbating factors'</a>). Sensitivity to cow's milk, soy, and egg white protein has also been reported to trigger CVS attacks in some children [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H11"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The essential features of CVS are recurring episodes of vomiting with a stereotypical pattern regarding time of onset and duration (hours to days), accompanying symptoms and signs (eg, pallor, lethargy), and the absence of vomiting between episodes  (<a class="graphic graphic_table graphicRef62483" href="/d/graphic/62483.html" rel="external">table 2</a>). Other common features include a history in the patient or family history of migraine headaches; the self-limited nature of the attacks; associated symptoms of nausea, abdominal pain, headache, motion sickness, and photophobia; and associated signs of profound lethargy and pallor (especially in children), excess salivation, diarrhea, dehydration, and social withdrawal. (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H3326457196"><span class="h2">Children and adolescents</span><span class="headingEndMark"> — </span>In children and adolescents, the specific pattern of vomiting episodes is variable but usually remains stereotypical for an individual patient [<a href="#rid1">1,4</a>]. In general, CVS episodes tend to begin in the early morning hours (2:00 to 7:00 AM) and last approximately the same duration. Most have a prodromal period of pallor, anorexia, nausea, abdominal pain, and/or lethargy  (<a class="graphic graphic_table graphicRef62483" href="/d/graphic/62483.html" rel="external">table 2</a>). The attacks usually last an average of 24 to 48 hours, although they may last up to 7 to 10 days. Approximately one-half of children have attacks at regular intervals, commonly occurring every two to four weeks, while the remainder have unpredictable intervals between episodes. Approximately three-quarters of parents can identify triggers, which are usually psychological (typically more excitement, eg, birthdays, rather than negative stressors) or infectious (eg, upper respiratory) events [<a href="#rid58">58</a>].</p><p>The clinical picture of CVS has gradually expanded to recognize that the recurring vomiting is often accompanied by multiple comorbid conditions that affect the patient even between vomiting episodes:</p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety – The most prevalent comorbidity is anxiety, which affects 47 percent of (59 percent of school-aged) children with CVS [<a href="#rid59">59</a>]. In fact, the lower health-related quality of life in CVS patients correlated with trait anxiety and coping abilities rather than with medical severity (frequency, duration of episodes) [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postural orthostatic tachycardia syndrome (POTS) – POTS is common in adolescents with CVS (14 percent in one pediatric case series and 38 percent of screened adolescents [<a href="#rid60">60</a>]). There is evidence of altered autonomic tone at baseline with elevated sympathetic tone and low to normal parasympathetic tone [<a href="#rid29">29,30</a>] (see <a class="local">'Autonomic dysfunction'</a> above). Management of POTS in adolescents with CVS, consisting of fluid and salt supplementation, <a class="drug drug_general" data-topicid="8455" href="/d/drug information/8455.html" rel="external">fludrocortisone</a> and low-dose <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, can reduce the frequency of vomiting episodes [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coalescent CVS – Some pediatric patients initially have a typical episodic pattern of CVS but later develop chronic daily nausea between vomiting episodes. The nausea typically peaks in the morning, affects approximately 12 percent of pediatric patients with CVS, and is most common in adolescent girls [<a href="#rid34">34,60</a>]. Some may outgrow the episodic vomiting entirely, and the persisting nausea may be then diagnosed as functional nausea. In the absence of an effective antinausea agent, it is difficult to treat. Anecdotally, <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> and <a class="drug drug_general" data-topicid="9392" href="/d/drug information/9392.html" rel="external">doxylamine-pyridoxine</a> improve symptoms for some patients [<a href="#rid61">61</a>]. The term "coalescent" CVS has been used to classify this pattern in pediatric patients, although the term is imprecise.</p><p></p><p class="headingAnchor" id="H3516866797"><span class="h2">Adults</span><span class="headingEndMark"> — </span>In adults, 93 percent described a prodrome of nausea, epigastric pain, or headache; early morning onset of vomiting; abdominal pain during episodes; and a high peak rate of vomiting of eight emeses per hour during the emetic phase [<a href="#rid56">56</a>]. Other common features include erosive esophagitis during or shortly after a vomiting episode, association with menstrual cycles or pregnancy, and a history of migraine headaches in self or family [<a href="#rid2">2,24,25</a>]. Postural orthostatic tachycardia may be present. In two series of adults with CVS, approximately one-third experienced either orthostatic tachycardia or hypotension [<a href="#rid24">24,44</a>].</p><p>Although there are similarities in CVS across age groups [<a href="#rid15">15</a>], some key differences between adults and children have been observed  (<a class="graphic graphic_table graphicRef62483" href="/d/graphic/62483.html" rel="external">table 2</a>) [<a href="#rid25">25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Frequency – Adult patients with adult-onset CVS tend to have less frequent symptoms compared with adult patients with pediatric-onset CVS (approximately four cycles per year, compared with 12 cycles per year, respectively) [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Duration – Adults tend have longer episodes of CVS compared with children (mean duration six versus two days).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age of onset – The age of onset is highly variable in adults, while in children, the age of onset is predominantly in the toddler or preschool years. In those whose episodes begin in adolescence, episodes persist well into adulthood [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Triggers – Triggering events may be less common in adults.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interepisodic nausea – Nausea between episodes is more common in adults compared with children (40 to 63 percent versus 12 percent)  (<a class="graphic graphic_figure graphicRef54863" href="/d/graphic/54863.html" rel="external">figure 1</a>) [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Behavioral symptoms – Two notable behaviors are more common in adults than in children: the use of hot-water showers or bathing to attenuate the nausea (56 percent), even in the absence of cannabis use, and rapid drinking of fluids followed by vomiting (apparently to dilute the bitterness of the bile). These behaviors do not indicate a factitious or psychiatric etiology [<a href="#rid62">62</a>]. Nearly one-half (44 percent) of adults with CVS had a history of physical or sexual abuse as a child, and two-thirds have had panic anxiety [<a href="#rid4">4</a>].</p><p></p><p>Case series of adult patients with CVS reflect difficulty and delays in establishing the diagnosis, often with repeat imaging and endoscopic studies and sometimes with surgical procedures such as cholecystectomy, pyloroplasty, or fundoplication without improvement [<a href="#rid2">2,25,56</a>]. This may reflect the frequent presence of interepisodic symptoms between acute vomiting episodes in adults with CVS and the limited awareness of CVS among clinicians caring for adults.</p><p>There may be an overlap between CVS and idiopathic gastroparesis in adults. Approximately 11 percent of adults with idiopathic gastroparesis have a cyclic pattern of symptoms and some respond to tricyclic antidepressants, similar to patients with CVS [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">NATURAL HISTORY</span><span class="headingEndMark"> — </span>Many children outgrow CVS by their preteen or early teenage years [<a href="#rid64">64</a>]. However, we have estimated that up to 75 percent of children with CVS will then develop migraine headaches by age 18 [<a href="#rid1">1,19</a>]. Some children who progress from CVS to migraine headaches will first pass through a phase of abdominal migraines [<a href="#rid65">65</a>]. Abdominal migraines can be distinguished from CVS in that the core symptom of abdominal migraines is abdominal pain, with little or no vomiting. Both syndromes may have headache as a feature and respond to antimigraine therapy [<a href="#rid1">1</a>]. One retrospective study of 51 children followed for up to 13 years found that vomiting resolved in 60 percent [<a href="#rid66">66</a>]. However, despite resolution of vomiting, 42 percent continued to have regular headaches and 37 percent had abdominal pain.</p><p>The natural history in adults has not been well studied. In the series of 17 adults described above [<a href="#rid25">25</a>], 13 had at least a partial response to tricyclic antidepressant therapy, while an additional three responded to other types of treatment. One patient had resolution off of medication during two years of follow-up. Nonresponders to tricyclic antidepressants compared with responders were more likely to have coalescent symptoms, have poor compliance, use narcotics, have more severe symptoms with longer episodes, and have more emergency department visits [<a href="#rid2">2,24</a>].</p><p class="headingAnchor" id="H13"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of CVS is based on the clinical history and exclusion of alternative diagnoses  (<a class="graphic graphic_table graphicRef57659" href="/d/graphic/57659.html" rel="external">table 3</a>). Two sets of criteria have been proposed based upon a consensus of experts:</p><p class="headingAnchor" id="H15"><span class="h2">Pediatric criteria</span><span class="headingEndMark"> — </span>The pediatric criteria for diagnosis of CVS developed by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) require all of the following [<a href="#rid6">6,9,67</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>At least five attacks in any interval or a minimum of three attacks during a six-month period</p><p class="bulletIndent1"><span class="glyph">●</span>Episodic attacks of intense nausea and vomiting lasting one hour to 10 days and occurring at least one week apart</p><p class="bulletIndent1"><span class="glyph">●</span>Stereotypical pattern and symptoms in the individual patient</p><p class="bulletIndent1"><span class="glyph">●</span>Vomiting during attacks occurs at least four times per hour for at least one hour</p><p class="bulletIndent1"><span class="glyph">●</span>Return to baseline health between episodes</p><p class="bulletIndent1"><span class="glyph">●</span>Not attributed to another disorder</p><p></p><p>The NASPGHAN guideline summarizes the diagnostic process in an algorithm  (<a class="graphic graphic_algorithm graphicRef53337" href="/d/graphic/53337.html" rel="external">algorithm 1</a>) [<a href="#rid9">9</a>].</p><p>A separate set of diagnostic criteria for CVS were developed in 2016 (pediatric Rome IV criteria) [<a href="#rid6">6,67</a>]. These differ from the NASPGHAN criteria by including those children with a minimum of two episodes and eliminating the quantitative severity of vomiting of as least four times per hour at the peak. These criteria could result in a higher sensitivity but possibly lower specificity than the NASPGHAN criteria.</p><p class="headingAnchor" id="H14582537"><span class="h2">Adult criteria</span><span class="headingEndMark"> — </span>Criteria for diagnosis of CVS in adults (adult Rome IV criteria) are [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stereotypical episodes of vomiting regarding onset (acute) and duration (less than one week)</p><p class="bulletIndent1"><span class="glyph">●</span>Three or more discrete episodes in the prior year and two episodes in the past six months, occurring at least one week apart</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of vomiting between episodes, but other milder symptoms can be present between cycles</p><p></p><p>A history or family history of migraine headaches further supports the diagnosis.</p><p class="headingAnchor" id="H789605"><span class="h2">Exclusion of other causes of vomiting</span><span class="headingEndMark"> — </span>CVS should be considered among other diagnoses in patients presenting with nausea and vomiting. (See  <a class="medical medical_review" href="/d/html/2537.html" rel="external">"Approach to the adult with nausea and vomiting"</a> and  <a class="medical medical_review" href="/d/html/5902.html" rel="external">"Approach to the infant or child with nausea and vomiting"</a>.)</p><p class="headingAnchor" id="H923539013"><span class="h3">Alarm symptoms and signs</span><span class="headingEndMark"> — </span>Alarm symptoms and signs alerting the clinician to a diagnosis other than CVS include the following; these were developed in the pediatric consensus statement but generally apply to adults as well [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal</p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal bleeding (other than mild hematemesis developing during an episode of vomiting, which suggests a prolapse gastropathy or Mallory-Weiss tear)</p><p class="bulletIndent2"><span class="glyph">•</span>Unilateral abdominal pain</p><p class="bulletIndent2"><span class="glyph">•</span>Bilious vomiting (bilious vomiting is quite common in CVS but warrants further evaluation to exclude intestinal obstruction)</p><p class="bulletIndent2"><span class="glyph">•</span>Weight loss</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic</p><p class="bulletIndent2"><span class="glyph">•</span>In toddlers, episodes triggered by fasting, illness, or high-protein meal, or by marked anion gap acidosis, hypoglycemia, or hyperammonemia </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic</p><p class="bulletIndent2"><span class="glyph">•</span>Severe headaches (especially if continuous or worsening rather than episodic)</p><p class="bulletIndent2"><span class="glyph">•</span>Altered mental status</p><p class="bulletIndent2"><span class="glyph">•</span>Gait disturbances or other new neurologic signs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other</p><p class="bulletIndent2"><span class="glyph">•</span>Severe clinical course characterized by failure to respond to treatment, progressive worsening, prolonged episodes requiring hospitalization</p><p class="bulletIndent2"><span class="glyph">•</span>A change in the vomiting pattern or symptoms</p><p></p><p class="headingAnchor" id="H1675692511"><span class="h3">Considerations for children</span><span class="headingEndMark"> — </span>Further steps depend upon the absence or presence of warning signs:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alarm signs absent</strong> – Children who present with the typical symptoms of CVS as outlined above and with no warning symptoms require only a limited screening evaluation to exclude other disorders:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Imaging – An upper gastrointestinal series to the ligament of Treitz should be performed in all children to exclude intestinal malrotation or nonfixation with possible intermittent volvulus [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/d/html/6477.html" rel="external">"Intestinal malrotation in children"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory testing – During at least one episode, laboratory testing should be performed, consisting of electrolytes, glucose, blood urea nitrogen (BUN), creatinine, and urinalysis. The primary purpose of these tests is to monitor for hypovolemia and electrolyte disturbances that can result from protracted vomiting, and chronic renal or Addison disease. Mild metabolic acidosis, hypoglycemia, and ketosis are consistent with CVS. Severe acidosis or hypoglycemia warrant further evaluation for an inborn error of metabolism, especially in infants and toddlers. (See  <a class="medical medical_review" href="/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Trial of prophylactic therapy – For patients whose symptoms warrant a trial of prophylactic therapy, the diagnosis of CVS is further supported if the CVS improves. Children who do not respond to prophylactic therapy may warrant further evaluation to identify other possible causes of the symptoms. (See <a class="local">'Prophylactic medications'</a> below.)</p><p></p><p class="bulletIndent1">For children with no alarm signs and typical symptoms, a provisional diagnosis of CVS can be made on the basis of the clinical history and basic testing outlined above. An extensive evaluation is not recommended because of low yield and high costs [<a href="#rid1">1,69</a>]. As an example, among 225 children with recurring cyclical episodes of vomiting who were evaluated extensively, only one in eight were found to have an underlying disorder that required intervention [<a href="#rid70">70</a>]. In a separate study, the results of systematic laboratory, radiographic, and endoscopic testing (cost of $6125 per child) altered management in only 4 percent [<a href="#rid69">69</a>]. A cost-decision analysis concluded that a more cost-effective diagnostic strategy in children was to obtain an upper gastrointestinal series to rule out malrotation and the possibility of subsequent volvulus, followed by a two-month trial of antimigraine therapy, with further studies reserved for those with continued symptoms [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alarm signs present</strong> – In the presence of alarm signs, further evaluation is recommended:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute-onset unilateral or flank pain – Perform an abdominal ultrasound to exclude acute hydronephrosis (so-called Dietl crisis). In a case series of four children, acute hydronephrosis caused by ureteropelvic junction obstruction closely mimicked symptoms of CVS [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/d/html/6585.html" rel="external">"Congenital ureteropelvic junction obstruction", section on 'Clinical presentation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Metabolic warning signs – For young children with characteristics suggesting metabolic disease (eg, episodes triggered by fasting, illness or a high-protein meal), measure serum concentrations of lactate, pyruvate, ammonia and serum amino acids, and urine organic acids. These tests should be performed during the early part of the episode, prior to administration of intravenous fluids.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neurologic signs – Perform a magnetic resonance imaging scan of the brain and/or evaluation for epilepsy [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Upper gastrointestinal bleeding – If upper gastrointestinal bleeding is severe or persistent, perform an endoscopic evaluation. Patients with CVS may have endoscopic evidence of prolapse gastropathy or Mallory-Weiss tear due to repetitive forceful vomiting.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Upper gastrointestinal symptoms that persist between episodes – Perform an upper endoscopy between episodes. If endoscopy is performed during or shortly after an episode of CVS, the presence of esophagitis does not imply that reflux is an underlying cause, since one-half of patients with CVS may have esophageal inflammation that does not require chronic antireflux treatment.</p><p></p><p class="headingAnchor" id="H2260707160"><span class="h3">Considerations for adults</span><span class="headingEndMark"> — </span>In adults, guidelines recommend biochemical, endoscopic, and sometimes radiographic assessments [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Biochemical testing is recommended to include a complete blood count, serum electrolytes, glucose, hepatic aminotransferases and pancreatic lipase, and urinalysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An esophagogastroduodenoscopy is also recommended, even though common findings of Mallory-Weiss tear and mild esophagitis are likely to be epiphenomenon.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging may be considered for very selected patients who have localized pain or other symptoms suggesting an organic cause.</p><p></p><p class="headingAnchor" id="H17"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Management of CVS involves:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lifestyle interventions</strong> to reduce the risk of inducing an attack and improve self-efficacy and quality of life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong>, provided during any severe bout of cyclic vomiting. This may include admission to the emergency department and/or hospital, intravenous fluids, antiemetics (including those with beneficial sedating effects), and analgesics. (See <a class="local">'Supportive care and antiemetics'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abortive medication</strong> used during the prodrome to prevent or attenuate the attack. This approach may be sufficient for patients with relatively mild or infrequent symptoms and, if possible, should be initiated at home. (See <a class="local">'Abortive medications (for prodrome)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylactic medication</strong> for selected patients, given daily to prevent further episodes. This approach is generally reserved for patients with frequent prolonged or severe symptoms. (See <a class="local">'Prophylactic medications'</a> below.)</p><p></p><p>The recommendations for management are summarized in the tables  (<a class="graphic graphic_table graphicRef77478 graphicRef78562 graphicRef68579" href="/d/graphic/77478.html" rel="external">table 4A-C</a>). Referral to a pediatric consultant, pediatric gastroenterologist, neurologist, or metabolic specialist is indicated for children with frequent or severe disabling episodes or mild episodes that persist despite lifestyle changes, supportive care, and a therapeutic trial. Similarly, adults should be referred to a specialist familiar with CVS if episodes are severe or disabling and initial interventions are not effective. Management of CVS in adults is outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef128378" href="/d/graphic/128378.html" rel="external">algorithm 2</a>).</p><p class="headingAnchor" id="H1141544045"><span class="h2">Lifestyle interventions</span><span class="headingEndMark"> — </span>Lifestyle modifications to reduce the risk of inducing an attack include adequate fluid intake, avoidance of fasting, using long-acting caloric snacks, good sleep hygiene, and regular exercise. Recognized precipitating factors should be avoided whenever feasible. In children, common triggers include physical exhaustion from lack of sleep, stressors such as bullying at school, motion (car rides, amusement park rides), fasting, and certain foods (eg, chocolate, cheese, cow's milk). In adults, precipitating factors are somewhat less common than in children but may include sleep disruptors (shift work, extended travel across time zones) and psychological stressors related to interpersonal conflict at work or home. If there as a history or prolonged and frequent cannabis use, total abstention can clarify whether this is cannabis hyperemesis syndrome (CHS) or CVS.</p><p>Management should address comorbid conditions as well. First among them is anxiety, panic attacks, or depression, which are present in 30 to 50 percent of children or adults with CVS [<a href="#rid10">10,73-75</a>]. Referral to a medical psychologist for cognitive behavioral therapy is an integral part of our program's treatment plan, and behavioral intervention can result in reduced disease severity. In more severe cases, the addition of anxiolytic agents (eg, <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>) may be necessary. If school absenteeism fails to respond to a graded school-reentry plan, a comprehensive biobehavioral rehabilitation program may be needed for recovery.</p><p>Understanding of and adherence to the treatment plan can be aided by a visual chart of the overall action plan, suitable for patients or caregivers with low literacy [<a href="#rid76">76</a>]. A sample can be accessed at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwrnmmc.libguides.com%2Fpediatrics%2FUSAP&amp;token=RBnP4m%2FpCJe9IlCNsYt2yR17xGU0UH374Q9BYevBBF%2BXfZspIPcL9IGVLVhSkpdyKN20AWJrFpcrjK6mWCf%2Fkw%3D%3D&amp;TOPIC_ID=2588" target="_blank">Darnall Medical Library</a>.</p><p class="headingAnchor" id="H3501372481"><span class="h2">Supportive care and antiemetics</span><span class="headingEndMark"> — </span>Supportive or rescue care is provided during an episode of vomiting to alleviate symptoms and complications. Once the vomiting becomes well established after several hours, the episode typically cannot be aborted and must run its usual course. The goal then becomes one of alleviating symptoms including vomiting, nausea, abdominal pain, and headache and replenishing fluid, energy, and electrolytes. A single-center review of pediatric visits for CVS found that delayed presentation to the emergency department &gt;24 hours after onset of symptoms and delay in administration of antiemetics in the emergency department were associated with higher rates of hospitalization [<a href="#rid77">77</a>]. This confirms the clinical observation that prompt intervention helps to attenuate the severity of episodes.</p><p>For supportive care of patients with CVS, the following strategies are often used, based on limited evidence  (<a class="graphic graphic_table graphicRef78562" href="/d/graphic/78562.html" rel="external">table 4B</a>) [<a href="#rid10">10,78</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous hydration</strong> – Intravenous hydration can decrease the frequency of vomiting and duration of episodes [<a href="#rid79">79</a>] in approximately one-half of patients, based on clinical experience [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>First, hypovolemia should be corrected with one or more fluid boluses (eg, isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> 10 to 20 mL/kg, or 1 L in adults) as needed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subsequently or simultaneously (piggy-backed), additional intravenous hydration should be given using half-normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> (0.45% NaCl) with 10% dextrose for children and normal saline (0.9% NaCl) with 5% dextrose for adults [<a href="#rid10">10</a>]. The solution should be infused at 1.5 times the maintenance rate. The rationale for including dextrose is that this may attenuate the catabolic state and ketosis induced by the acute CVS episode, which can prolong vomiting. For patients with significant electrolyte derangements (hypokalemia, hypochloremia, and hyponatremia), adjustments to intravenous fluids are discussed separately. (See  <a class="medical medical_review" href="/d/html/6103.html" rel="external">"Treatment of hypovolemia (dehydration) in children in resource-abundant settings"</a> and  <a class="medical medical_review" href="/d/html/2296.html" rel="external">"Maintenance and replacement fluid therapy in adults"</a>.)</p><p></p><p class="bulletIndent1">In children, persistent moderate to severe anion gap acidosis or hypoglycemia should prompt further evaluation for a metabolic disorder, even though striking elevations of urinary acetoacetate and beta-hydroxybutyrate (on organic acid profiles) can be found during episodes of CVS. (See <a class="local">'Considerations for children'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Environment</strong> – Some patients benefit from staying in a quiet, dark room with limited vital sign checks to reduce sensory stimulation, which can exacerbate episodes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Feeding</strong> – Provision of calories during the emetic phase is thought to help children with mitochondrial variants of CVS and suspected disorders of carbohydrate or fat metabolism. However, most children can only tolerate delivery by parenteral or jejunal routes, which is usually not feasible unless the patient has a jejunal access device in place. Once vomiting has ceased during the recovery, initiation of frequent small feedings with low-fat foods is important for nutritional recovery. (See <a class="local">'Mitochondrial dysfunction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiemetics</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ondansetron</strong> – Use of <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a>, a 5-hydroxytryptamine (5-HT<sub>3</sub>) receptor antagonist, is recommended for use in emergency and inpatient settings to reduce the frequency of emesis and fluid requirements [<a href="#rid78">78</a>]. Parenteral ondansetron, even if administered early, may attenuate the vomiting but usually does not abort the episode and does not reduce the unrelenting nausea. In the available cases series, 50 to 75 percent of patients reported improvement with intravenous ondansetron [<a href="#rid19">19,78,79</a>].</p><p></p><p class="bulletIndent2">Dosing for <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a> is:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children – 0.3 mg/kg/dose, up to a maximum of 8 mg. May give an additional dose every four to six hours, with a maximum total dose of 32 mg/24 hours.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Adults – 8 mg intravenously. May give an additional 8 mg dose every four to six hours, with a maximum total dose of 32 mg/24 hours [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent2">Use with caution in patients with risk factors for<sub> </sub>QT<sub>c</sub> prolongation, including other medications that also prolong the QT interval, such as tricyclic antidepressants and phenothiazine antiemetics or family history of sudden death.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fosaprepitant</strong> – Our program uses intravenous <a class="drug drug_general" data-topicid="9032" href="/d/drug information/9032.html" rel="external">fosaprepitant</a> as an alternative to intravenous <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a> as it appears to be more effective with fewer side effects, based on our anecdotal experience. We use the following dosing:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children 2 to &lt;12 years – 3 to 4 mg/kg intravenously over 60 minutes (maximum dose 150 mg). If needed, administer 2 mg/kg intravenously (<a class="drug drug_general" data-topicid="9032" href="/d/drug information/9032.html" rel="external">fosaprepitant</a>) or orally (<a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a>) on days 2 and 3.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children ≥12 years and adults – 150 mg intravenously over 30 minutes. If needed, administer 80 mg intravenously (<a class="drug drug_general" data-topicid="9032" href="/d/drug information/9032.html" rel="external">fosaprepitant</a>) or orally (<a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a>) on days 2 and 3.</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9032" href="/d/drug information/9032.html" rel="external">Fosaprepitant</a> has a large evidence base from treatment of chemotherapy-induced nausea and vomiting [<a href="#rid81">81</a>]. Dosing for CVS is not standardized and varies among centers but is generally similar to that used for chemotherapy-induced vomiting, with minor variations for days 2 and 3 including route of administration and as-needed dosing.</p><p></p><p class="bulletIndent1">Triptan therapy (eg, <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a>) may be useful if the patient presents to the emergency department in the very early phases of the episode (ie, within one hour of the onset of vomiting), but this is rarely the case [<a href="#rid10">10</a>]. (See <a class="local">'Abortive medications (for prodrome)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sedating agents</strong> – Because vomiting is not completely controlled by a 5-HT<sub>3</sub> antagonist therapy alone, we usually add a medication with both antiemetic and sedating effects (eg, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> or <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>).</p><p></p><p class="bulletIndent1">Data on the use of these medications in this setting are extremely limited. The practice of using medications with a sedating effect is based largely on clinical observations that induction of deep sleep may alleviate both nausea and vomiting in some cases or stop episodes already in progress. Occasionally, administration of benzodiazepines or use of closely monitored general anesthesia using <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a> will terminate an episode [<a href="#rid82">82</a>]. The efficacy of these medications for severe and intractable vomiting is also supported by experience with these drugs in other settings (eg, chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting, cannabinoid hyperemesis) [<a href="#rid51">51</a>]. In pediatric practice, we often begin with <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> and if sedation is inadequate, we switch to <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>. Adult guidelines are similar but suggest initiating treatment with lorazepam [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a> and  <a class="medical medical_review" href="/d/html/16849.html" rel="external">"Postoperative nausea and vomiting"</a> and  <a class="medical medical_review" href="/d/html/141176.html" rel="external">"Cannabinoid hyperemesis syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antihypertensives</strong> – Most patients with mild hypertension during an acute CVS episode do <strong>not</strong> require antihypertensive therapy, since the hypertension usually resolves as the patient's discomfort improves. A small subset of patients (those with the Sato variant of CVS) may present with more severe and persistent hypertension (see <a class="local">'Hypothalamic-pituitary-adrenal axis hyperreactivity'</a> above). If pharmacologic therapy is needed for such patients, short-acting antihypertensives can be used as needed during the episode. Prolonged use of antihypertensives is not necessary, because the hypertension abates with resolution of the CVS episode.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other medications</strong> – Management of abdominal and headache pain usually begins with the nonsteroidal antiinflammatory drug intravenous <a class="drug drug_general" data-topicid="8591" href="/d/drug information/8591.html" rel="external">ketorolac</a>. This approach is supported by our clinical experience and the theoretical mechanism that it reduces elevated prostaglandin E2. Oral or intravenous <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> also may be trialed but may be less effective than ketorolac, based on anecdotal clinical experience. If possible, narcotics should be avoided as they can worsen vomiting and induce dependence over time.</p><p></p><p>For adults, there is only anecdotal experience on the efficacy of the above antiemetics, sedating agents, and analgesics used for supportive care [<a href="#rid40">40,83,84</a>]. A variety of other antiemetic medications have been used, including high-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>, and <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a>, but these are usually unsuccessful [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H2523266804"><span class="h2">Abortive medications (for prodrome)</span><span class="headingEndMark"> — </span>Abortive medications should be administered to any patient with known CVS if they can be given during the prodrome or shortly after the vomiting begins. The medications should be administered promptly after the patient presents to the emergency department. Patients with delayed intervention (especially &gt;24 hours after symptom onset) are more likely to require hospital admission [<a href="#rid77">77</a>].</p><p>Abortive therapy alone is generally suggested for patients with relatively mild or infrequent episodes. For those with frequent or severe symptoms, abortive therapy may be used in conjunction with ongoing prophylactic therapy. (See <a class="local">'Prophylactic medications'</a> below.)</p><p>The primary choices for abortive medication in both children and adults are <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> and <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a> (a neurokinin 1 antagonist)  (<a class="graphic graphic_table graphicRef78562" href="/d/graphic/78562.html" rel="external">table 4B</a>).</p><p class="headingAnchor" id="H3939998781"><span class="h3">Children and adolescents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sumatriptan</strong> – For children with migraine-associated CVS, <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> is moderately effective if given early in the prodromal phase and may have some effect if given within one hour after onset of vomiting. In one small case series, sumatriptan had a 54 percent response rate when given subcutaneously and 33 percent when given intranasally [<a href="#rid41">41</a>]. It may be tried in those without a family history of migraines because it can be effective in some. It appears to be more effective when the episodes are shorter in duration (&lt;1 day) in children. Our approach is to first do a trial by the intranasal route. If symptoms persist, the dose can be repeated once in two hours. However, if intranasal administration fails to alleviate symptoms, we may proceed to a trial of a subcutaneous sumatriptan injection during the next episode of vomiting. In general, sumatriptan either is completely effective or wholly ineffective in terminating an episode.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">Sumatriptan</a> dosing is not well established, especially for young children. We use the following doses for CVS, based on clinical experience and a few published case series [<a href="#rid39">39,41</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age 5 to 11 years, or weight 20 to 39 kg – Intranasal dose 5 to 10 mg <strong>or</strong> subcutaneous dose 2 to 3 mg</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age 12 to 17 years, or weight 40 to 59 kg – Intranasal dose 20 mg <strong>or</strong> subcutaneous dose 3 to 6 mg</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age ≥18 years, or weight ≥60 kg – Intranasal dose 20 mg <strong>or</strong> subcutaneous dose 6 mg</p><p></p><p class="bulletIndent1">A repeat dose may be given in two hours for intranasal administration and one hour for subcutaneous administration. The nasal form causes a bitter aftertaste, which can be lessened by flexing the head forward to avoid dripping spray into the nasopharynx. The subcutaneous dose can induce a pronounced transient burning in the chest and neck region. Triptans are contraindicated in those with known coronary or peripheral vascular disease and those with complex (eg, basilar) migraines.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aprepitant</strong> – As an alternative, <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a>, an oral neurokinin 1 antagonist antiemetic, can be used if it can be given during the prodrome at least 30 minutes before the onset of vomiting with subsequent dosing on days 2 and 3. Aprepitant is particularly appropriate for patients with no family history of migraine or who failed to respond to triptans.</p><p></p><p class="bulletIndent1">Abortive dosing of <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a> varies by body weight:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children &lt;15 kg – 80 mg orally on day 1 and 40 mg on days 2 and 3</p><p class="bulletIndent2"><span class="glyph">•</span>Children 15 to 20 kg – 80 mg orally once daily for three days</p><p class="bulletIndent2"><span class="glyph">•</span>Children &gt;20 kg – 125 mg orally on day 1 and 80 mg on days 2 and 3</p><p></p><p class="bulletIndent1">Among 25 children who were able to take oral <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a> 30 minutes before vomiting, 76 percent achieved at least a partial response [<a href="#rid85">85</a>].</p><p></p><p class="headingAnchor" id="H2205751093"><span class="h3">Adults</span><span class="headingEndMark"> — </span>We suggest <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> as the first-line abortive agent, using an intranasal dose of 20 mg or subcutaneous dose of 6 mg  (<a class="graphic graphic_algorithm graphicRef128378" href="/d/graphic/128378.html" rel="external">algorithm 2</a>). Based upon experience from treating migraines, the subcutaneous route is likely more effective than the nasal one. If sumatriptan is not effective, the second-line choice is a trial of <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a>, using 125 mg orally on day 1 and 80 mg on days 2 and 3. These suggestions reflect expert opinion, based on low-quality evidence from case reports and clinical experience, as reviewed in the adult guideline [<a href="#rid10">10</a>].</p><p><a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">Ondansetron</a> administered orally before vomiting, beginning at home or intravenously in the emergency department, rarely aborts an episode but can reduce the pace and amount of vomiting and may circumvent the need for parenteral fluids [<a href="#rid9">9</a>]. (See <a class="local">'Supportive care and antiemetics'</a> above.)</p><p class="headingAnchor" id="H2540764564"><span class="h2">Prophylactic medications</span><span class="headingEndMark"> — </span>The decision to use prophylactic medications depends upon the frequency and severity of the attacks, similar to the principles that guide treatment of patients with migraine headaches [<a href="#rid31">31</a>]. In general, prophylactic therapy is warranted if attacks occur more than monthly or last more than one to two days in a child or adolescent, or &gt;4 episodes/year or last &gt;2 days in an adult, or are severe enough to require hospitalization or cause substantial school absenteeism or work disability. Abortive therapy may be used in addition to prophylactic therapy for patients who continue to have breakthrough vomiting episodes. (See <a class="local">'Abortive medications (for prodrome)'</a> above.)</p><p class="headingAnchor" id="H2373259789"><span class="h3">Children and adolescents</span><span class="headingEndMark"> — </span>In children, prophylactic agents that have been used with variable success include antimigraine agents (<a class="drug drug_general" data-topicid="9311" href="/d/drug information/9311.html" rel="external">cyproheptadine</a>, <a class="drug drug_general" data-topicid="10091" href="/d/drug information/10091.html" rel="external">pizotifen</a>, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a>, <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>), antiemetics (<a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a>, <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a>), and anticonvulsants (<a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>) [<a href="#rid85">85-87</a>]. Adjunctive treatment with mitochondrial supplements (coenzyme Q10, L-carnitine, <a class="drug drug_general" data-topicid="9861" href="/d/drug information/9861.html" rel="external">riboflavin</a>) is often added to the preventative regimen, based on limited evidence and with wide variation in practice [<a href="#rid9">9,34-36,88</a>].</p><p>We use the following approach to selecting prophylactic medications, consistent with the 2008 North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Consensus Statement [<a href="#rid9">9</a>]. The limited evidence for the use of these medications for CVS suggests similar efficacy, so selection among these medications is guided primarily by side effects and toxicities, differences in clinician experience with use of each drug for CVS within a specific age group, and indirect experience from their use for migraine.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>First-line</strong> – As the initial first-line choice for prophylactic therapy, we suggest the following  (<a class="graphic graphic_table graphicRef68579" href="/d/graphic/68579.html" rel="external">table 4C</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children &lt;5 years – <a class="drug drug_general" data-topicid="9311" href="/d/drug information/9311.html" rel="external">Cyproheptadine</a> or <a class="drug drug_general" data-topicid="10091" href="/d/drug information/10091.html" rel="external">pizotifen</a>. Pizotifen is similar to cyproheptadine and is available outside of the United States.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children ≥5 years – <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">Amitriptyline</a>.</p><p></p><p class="bulletIndent1">The use of <a class="drug drug_general" data-topicid="9311" href="/d/drug information/9311.html" rel="external">cyproheptadine</a> for prophylactic therapy in patients with CVS is supported by several case series. Response rates (ie, at least partial reduction in the frequency and/or severity of episodes compared with baseline) reported in the available series range from 41 to 83 percent [<a href="#rid19">19,79,86,89,90</a>]. Its use for CVS is also supported by indirect experience of its use for migraine headaches in children. The recommendation favoring cyproheptadine over <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> in younger children was based primarily upon expert experience and respective side effect profiles. Cyproheptadine is generally well tolerated by young children; side effects may include excessive weight gain and sedation. Children should be monitored for these effects, and an alternative agent should be considered in children who are already overweight. In some cases, tachyphylaxis may arise and can be countered by intermittent dosing, achieved by either skipping this medication on weekends or skipping one week per month. Outside of the United States, <a class="drug drug_general" data-topicid="10091" href="/d/drug information/10091.html" rel="external">pizotifen</a>, a similar agent, may be used as first–line therapy, based on limited evidence [<a href="#rid91">91</a>]. (See  <a class="medical medical_review" href="/d/html/98355.html" rel="external">"Preventive treatment of migraine in children", section on 'Cyproheptadine'</a>.)</p><p></p><p class="bulletIndent1">The evidence supporting <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> as a first-line agent includes several large case series in children and adults, in which amitriptyline was the single most effective agent [<a href="#rid2">2,9,19,86,92</a>]; response rates in the available case series range from 70 to 90 percent [<a href="#rid19">19,25,34,79,86,90</a>]. Amitriptyline may be more effective for those with a personal or family history of migraine but should be tried in those without a migraine association. In one case series, amitriptyline and other antimigraine agents were effective in 79 percent of children with a history of migraines in the family or patient, compared with 36 percent in those with no history of migraines [<a href="#rid19">19</a>]. <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">Nortriptyline</a>, a less sedating alternative to amitriptyline, has also been successfully used in this population. (See  <a class="medical medical_review" href="/d/html/98355.html" rel="external">"Preventive treatment of migraine in children", section on 'Tricyclic medications'</a>.)</p><p></p><p class="bulletIndent1">Optimal tolerance of <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> requires gradual titration, monitoring (ie, electrocardiogram [ECG]), and, in some cases, obtaining therapeutic blood levels, especially in children on higher doses. A common starting dose is 0.2 to 0.3 mg/kg per day at bedtime, followed by increases in increments of 5 to 10 mg at weekly intervals to a higher dose, often 1 to 1.5 mg/kg per day at bedtime. This incremental dose increase allows for adaptation to side effects (eg, morning tiredness). Up to 50 percent of patients may experience anticholinergic (dry mouth, constipation) and sedative side effects (morning tiredness). ECG monitoring should be performed before starting and again 10 days after reaching the peak dose; cardiotoxicity (tachyarrhythmia) can be avoided by maintaining the QTc interval &lt;460 msec. It typically takes up to one to two months for the effects of amitriptyline to become fully evident once the target dose is reached. In some individuals, higher doses may be needed to control the CVS, but this should be approached with caution. (See <a class="local">'Nonresponders'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second-line</strong> – If the first-line agents are not effective after optimal titration, the next step is a trial of either <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a> or <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>  (<a class="graphic graphic_table graphicRef68579" href="/d/graphic/68579.html" rel="external">table 4C</a>).</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">Aprepitant</a> is a newer antiemetic agent that has good efficacy based on limited but increasing clinical experience in adults and children. When aprepitant is used for prophylaxis, it is administered at the following doses [<a href="#rid85">85</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children &lt;40 kg – 40 mg orally twice weekly</p><p class="bulletIndent2"><span class="glyph">•</span>Children 40 to 60 kg – 80 mg orally twice weekly</p><p class="bulletIndent2"><span class="glyph">•</span>Children &gt;60 kg and adults – 125 mg orally twice weekly</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">Aprepitant</a> is also used for abortive therapy, at higher doses, as described above. (See <a class="local">'Abortive medications (for prodrome)'</a> above.)</p><p></p><p class="bulletIndent1">In one retrospective series of 16 children treated prophylactically with <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a>, three (19 percent) achieved a complete response and 10 (62 percent) achieved a partial response [<a href="#rid85">85</a>]. For <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, response rates in the available case series range from 46 to 83 percent [<a href="#rid9">9,19,79,89</a>]. Propranolol was recommended as the second-line agent in the NASPGHAN consensus statement, which was written in 2008 before data on aprepitant became available [<a href="#rid9">9</a>]. Other agents that may be effective include the anticonvulsants <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> or <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>, or the antidepressant <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a> [<a href="#rid87">87,93,94</a>]. Although all have similar rates of efficacy, we suggest aprepitant or propranolol because of the substantive but reversible cognitive side effects associated with the use of anticonvulsants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive therapy</strong> – In addition to the first- or second-line therapies described above, we suggest a trial in children of adjunctive treatment with coenzyme Q10 and/or <a class="drug drug_general" data-topicid="10109" href="/d/drug information/10109.html" rel="external">L-carnitine supplements</a> and <a class="drug drug_general" data-topicid="9861" href="/d/drug information/9861.html" rel="external">riboflavin</a> for at least four months. All of these supplements are also used for mitochondrial disorders in children [<a href="#rid9">9</a>]. In some milder cases of CVS, these supplements may be effective as sole therapy rather than as adjuncts to other medications. Anecdotally, some children with limited physical stamina or chronic fatigue experience marked improvement on mitochondrial supplements, sometimes recognized only in hindsight.</p><p></p><p class="bulletIndent1">Retrospective studies support the efficacy of coenzyme Q10, L-carnitine, and <a class="drug drug_general" data-topicid="9861" href="/d/drug information/9861.html" rel="external">riboflavin</a> in children with CVS [<a href="#rid34">34-36,88</a>]. In one report based on surveys of parents, the response to coenzyme Q10 alone appeared similar to that of <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> [<a href="#rid34">34</a>]. In another retrospective study of 30 patients treated with a protocol consisting of fasting avoidance, coenzyme Q10 and L-carnitine supplementation, and, in refractory cases, with added amitriptyline or <a class="drug drug_general" data-topicid="9311" href="/d/drug information/9311.html" rel="external">cyproheptadine</a>, 90 percent achieved at least a 50 percent reduction in vomiting episodes [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For coenzyme Q10, a common starting dose is 10 mg/kg per day or 200 mg twice daily and target blood levels are &gt;3 to 4 microgram/mL. If blood levels of coenzyme Q10 are low, this may be the result of poor bioavailability and indicate the need for a higher dose or different preparation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alternatively or in addition, L-carnitine can be used. A typical starting dose for <a class="drug drug_general" data-topicid="10109" href="/d/drug information/10109.html" rel="external">L-carnitine supplements</a> is 50 or 100 mg/kg per day or 1 g twice daily. Higher doses (eg, up to 4 g/day) have been used if needed based on laboratory testing of blood carnitine levels (target free carnitine level &gt;40 micromol/L) [<a href="#rid35">35</a>]. However, high doses should be approached with caution and careful monitoring for adverse events, including dose-related diarrhea. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The suggested dosing for <a class="drug drug_general" data-topicid="9861" href="/d/drug information/9861.html" rel="external">riboflavin</a> is approximately 10 mg/kg per day divided into two daily doses; most often, doses of 100 or 200 mg twice daily are used [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1">If there is no apparent therapeutic benefit during a trial of at least four months, the supplements may be discontinued. These supplements are available without prescription. There are some combination powdered preparations that are easier for children to take and avoid the burden of multiple supplement pills (eg, Spectrum Needs brand).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stopping treatment</strong> – In children, CVS tends to persist for three to five years [<a href="#rid1">1,64</a>]. CVS often begins to improve around age 10 years and resolves by 18 years in approximately 75 percent of individuals, although the vomiting symptoms are often replaced by migraine headaches [<a href="#rid60">60,64</a>] (see <a class="local">'Natural history'</a> above). Therefore, we typically attempt weaning off of prophylactic medication for adolescents who have had no episodes for one to two years or done well with few episodes for three years. For practical reasons, we tend to wean the medication during the summer holidays when school is in recess.</p><p></p><p class="headingAnchor" id="H3605436434"><span class="h3">Adults</span><span class="headingEndMark"> — </span>The approach to prophylactic therapy in adults is similar to that in older children, with slight differences in priorities  (<a class="graphic graphic_table graphicRef68579" href="/d/graphic/68579.html" rel="external">table 4C</a> and <a class="graphic graphic_algorithm graphicRef128378" href="/d/graphic/128378.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>First-line</strong> – For adults who require prophylactic therapy for CVS, the first-line choice is <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, using doses of 75 to 100 mg per day [<a href="#rid2">2,25,84,92</a>]. Amitriptyline is more likely to be effective for patients with a personal or family history of migraines but also appears to be effective in those without such a history. A typical approach is to initiate a low dose of 10 to 25 mg at night and, if well tolerated, titrate upward based upon tolerance [<a href="#rid95">95</a>]. Its use may be limited by common side effects such as fatigue or sedation, confusion, headache, poor concentration, weight gain, constipation, palpitations, and lightheadedness, which may be dose-limiting. If these occur and are intolerable, treatment may be switched to alternative tricyclic antidepressants (<a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a>, <a class="drug drug_general" data-topicid="9390" href="/d/drug information/9390.html" rel="external">doxepin</a>) [<a href="#rid10">10,84,92</a>]. For some individuals, higher doses may be needed to control the CVS, but this should be approached with caution. (See <a class="local">'Nonresponders'</a> below.)</p><p></p><p class="bulletIndent1">This recommendation is based on evidence from open-label and retrospective studies. In a review of 14 studies that included 600 adult and pediatric patients with CVS treated with <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> or other tricyclic antidepressants, 70 percent reported complete or partial improvement with a decrease in frequency, duration, or severity of CVS symptoms [<a href="#rid10">10</a>]. Similarly, in an open-label study of 46 patients followed for two years, treatment with a tricyclic antidepressant was associated with marked reductions in the number of CVS episodes (from 17 to 3), duration of a CVS episode (from six to two days), and in the number of emergency department visits/hospitalizations (from 15 to 3) [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second–line</strong> – When tricyclic antidepressants fail to control attacks or are not tolerated, the anticonvulsants <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> (100 mg), <a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">zonisamide</a> (400 mg), and <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> (1000 mg) may be used [<a href="#rid2">2,10,96</a>]. In a retrospective review of 136 adults, 88 responded to topiramate with a significant 50 to 66 percent reduction in annual number of CVS episodes and CVS-related emergency department visits and hospitalizations [<a href="#rid97">97</a>]. Potential adverse effects of topiramate include cognitive dysfunction (8 to 12 percent at migraine dosages), paresthesia, headache, fatigue, dizziness, mood problems, and loss of appetite [<a href="#rid98">98,99</a>]. Alternatively, it is reasonable to do a trial of <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a> 125 mg twice a week, as suggested in guidelines based largely on the collective clinical experience of the panel [<a href="#rid10">10</a>]. There is minimal experience to support or refute the use of <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> for prophylaxis of CVS in adults, although indirect evidence from its use for migraines suggests that it might be effective for CVS. Further details on these drugs are discussed in separate topic reviews. (See  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults"</a> and  <a class="medical medical_review" href="/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Zonisamide'</a> and  <a class="medical medical_review" href="/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Levetiracetam'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive therapy</strong> – Mitochondrial supplements (coenzyme Q10, sometimes with <a class="drug drug_general" data-topicid="9861" href="/d/drug information/9861.html" rel="external">riboflavin</a>) are sometimes used as adjuncts to other prophylactic agents in adults and are discussed as options in the adult guideline [<a href="#rid10">10</a>]. Doses for adults are coenzyme Q10 200 mg orally twice daily and riboflavin 200 mg orally twice daily. This is based primarily upon very limited and indirect evidence for efficacy in prophylaxis of migraines in adults and prophylaxis of CVS in children. (See <a class="local">'Children and adolescents'</a> above and  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults"</a>.)</p><p></p><p class="headingAnchor" id="H4184525437"><span class="h3">Catamenial cyclic vomiting syndrome</span><span class="headingEndMark"> — </span>For adolescent or adult women with catamenial CVS (ie, when onset of episodes coincide with the onset of menses), addition or adjustment of hormonal contraceptives is an early consideration. Options include oral contraceptives (with either low doses of estrogen or progesterone-only) or intramuscular <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> every three months. In contrast, oral contraceptives with high doses of estrogen can also exacerbate symptoms in CVS patients [<a href="#rid9">9,100</a>]. The strategy is similar to that used for estrogen-associated menstrual migraine. (See  <a class="medical medical_review" href="/d/html/5441.html" rel="external">"Estrogen-associated migraine headache, including menstrual migraine"</a>.)</p><p class="headingAnchor" id="H4076607613"><span class="h3">Nonresponders</span><span class="headingEndMark"> — </span>In children, adolescents, and adults who remain refractory to the therapies recommended above, we suggest the following approach [<a href="#rid60">60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>First, reevaluate for the possibility of a recurring trigger such as school (eg, bully), work, or family stressors (eg, divorce). In children, an indolent infection such as chronic sinusitis can be a hidden trigger. In adults, chronic unrevealed use of cannabis or reliance on opioids for pain management may be triggers. (See <a class="local">'Lifestyle interventions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Second, in children, consider alternative causes of vomiting and screen for acute hydronephrosis or small bowel obstruction (volvulus) <strong>during</strong> the vomiting episode with an abdominal ultrasound or abdominal computed tomography. Some adolescents may evolve from CVS into a postprandial pattern of rumination or "coalescent" daily morning nausea and occasional vomiting that is much milder than that in a CVS episode. Adolescents and adults should avoid cannabis and opioids. Adults may benefit from an evaluation for gastroparesis. (See <a class="local">'Exclusion of other causes of vomiting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Third, revisit the possibility of treatment with <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, with further dose escalation (&gt;1.5 mg/kg dose) using careful titration, ECG monitoring, and therapeutic monitoring. In some children or adults, these higher doses may be needed to control the CVS, especially if the individual is a rapid metabolizer. Such patients may not respond to standard doses of amitriptyline (1 to 1.5 mg/kg per day) and have very low or undetectable blood levels of amitriptyline but may respond when the amitriptyline dose is further increased and blood levels reach therapeutic levels of 100 to 150 micrograms/L [<a href="#rid35">35</a>]. As a general rule, an ECG and blood amitriptyline level should be obtained before attempting to exceed 1.5 mg/kg per day. To avoid cardiotoxicity (tachyarrhythmia), the QTc interval should be maintained below a safe threshold (eg, &lt;460 msec for children and adolescents [<a href="#rid101">101</a>], &lt;470 msec for women, and &lt;450 msec for men [<a href="#rid10">10</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Finally, combination medical therapy may be effective, such as [<a href="#rid60">60,102</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">Amitriptyline</a> and an anticonvulsant (eg, <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">Amitriptyline</a> and <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">Amitriptyline</a> and <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">Propranolol</a> and <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a></p><p></p><p class="headingAnchor" id="H1052731678"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116020.html" rel="external">"Society guideline links: Nausea and vomiting"</a>.)</p><p class="headingAnchor" id="H20425773"><span class="h1">ADDITIONAL RESOURCES FOR PATIENTS</span><span class="headingEndMark"> — </span>Support and counseling may be helpful for selected patients. The Cyclic Vomiting Syndrome Association (CVSA), an international organization, was established in 1993 to provide support to patients with CVS. This and other resources that may be useful for patients are listed in the table  (<a class="graphic graphic_table graphicRef74868" href="/d/graphic/74868.html" rel="external">table 5</a>).</p><p class="headingAnchor" id="H2788684541"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15733.html" rel="external">"Patient education: Nausea and vomiting in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/131890.html" rel="external">"Patient education: Cannabis hyperemesis syndrome (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/1223.html" rel="external">"Patient education: Nausea and vomiting in infants and children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Cyclic vomiting syndrome (CVS) is an idiopathic disorder characterized by recurrent, stereotypical bouts of vomiting with intervening periods of normal or baseline health. Both children and adults are affected. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The pathogenesis of CVS remains unknown, and CVS may represent a heterogeneous group of disorders. An association between CVS and migraine headaches has been consistently described in the majority of patients, suggesting that there may be a common pathophysiologic process, but other mechanisms have been implicated, including, in some cases, chronic high-dose cannabis use. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Diagnostic criteria have been proposed based upon consensus of experts by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) for children  (<a class="graphic graphic_algorithm graphicRef53337" href="/d/graphic/53337.html" rel="external">algorithm 1</a>) and Rome IV Committees for children and adults. The specific pattern, severity, and duration of vomiting episodes varies among patients but is usually stereotypical for an individual patient. CVS is diagnosed based primarily upon the history and exclusion of alternative diagnoses  (<a class="graphic graphic_table graphicRef57659" href="/d/graphic/57659.html" rel="external">table 3</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute management</strong> – Management of CVS includes addressing lifestyle modifications and comorbidities, especially anxiety. Specific interventions depend on age of patient, severity of symptoms, timing of presentation, and setting. Our general approach is as follows (see <a class="local">'Lifestyle interventions'</a> above and <a class="local">'Management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prodromal and early symptoms (home management)</strong> – For patients with an episode of CVS that can be identified during the prodrome or shortly after the vomiting begins, we suggest treatment with an abortive agent such as intranasal or subcutaneous <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> or oral <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The choice between these options is based largely on patient and provider preference  (<a class="graphic graphic_table graphicRef78562" href="/d/graphic/78562.html" rel="external">table 4B</a>). Aprepitant is particularly appropriate for patients without a personal or family history of migraine and those who have failed to respond to triptans.</p><p></p><p class="bulletIndent2">Abortive treatments are most effective if they are given early in the prodrome and should be prescribed to have at home for timely use by the patient. (See <a class="local">'Abortive medications (for prodrome)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute vomiting episodes (emergency department management)</strong> – For patients who present to the emergency department with moderate to severe vomiting episodes, supportive care includes the following measures  (<a class="graphic graphic_table graphicRef78562" href="/d/graphic/78562.html" rel="external">table 4B</a>). Supportive care is more effective when the patient presents to the emergency department earlier, especially within six hours of onset, compared with waiting 24 or more hours from onset (see <a class="local">'Supportive care and antiemetics'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Intravenous hydration</strong> – Intravenous fluids should be given to replace fluid losses. Hypovolemia is initially corrected with fluid boluses (eg, 10 to 20 mL/kg of isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>). For ongoing maintenance fluid therapy in children, we suggest a half-normal saline (0.45% sodium chloride) with 10% dextrose rather than lower dextrose concentrations (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For adults, we typically use isotonic saline (0.9% sodium chloride) with 5% dextrose. This dextrose infusion may lessen the catabolic state and ketosis, which can prolong vomiting.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Antiemetic therapy</strong> – For patients presenting with acute vomiting episodes, we suggest initial treatment with high-dose 5-hydroxytryptamine (5-HT<sub>3</sub>) receptor antagonist (eg, <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a>, <a class="drug drug_general" data-topicid="8501" href="/d/drug information/8501.html" rel="external">granisetron</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). A possible alternative is intravenous <a class="drug drug_general" data-topicid="9032" href="/d/drug information/9032.html" rel="external">fosaprepitant</a>. In addition, we suggest concomitant treatment with an agent with both antiemetic and sedating effects (eg, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> or <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The sedating agent provides additional symptom relief, which is valuable because control of nausea and vomiting is often incomplete with 5-HT<sub>3</sub> receptor antagonist therapy.</p><p></p><p class="bulletIndent3">Triptan therapy (eg, <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a>) may be useful if the patient presents to the emergency department in the very early phases of the episode (ie, within one hour of the onset of vomiting), but this is rarely the case. (See <a class="local">'Abortive medications (for prodrome)'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Environmental measures</strong> – Whenever possible, the patient should be kept in a dark, quiet, low-stimulation environment because any disturbance of the hyperesthetic patient typically incites more nausea and vomiting.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Treatment of pain (if present)</strong> – Management of abdominal and headache pain usually begins with an intravenous nonsteroidal antiinflammatory drug (eg, <a class="drug drug_general" data-topicid="8591" href="/d/drug information/8591.html" rel="external">ketorolac</a>). If the pain has a midepigastric or dyspeptic quality, an antireflux medication (eg, histamine type 2 receptor antagonist or proton pump inhibitor) is reasonable adjunctive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylactic therapy</strong> – For patients who experience CVS episodes that are frequent, prolonged, or debilitating, or that result in recurrent emergency department or hospital admissions, we suggest prophylactic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Selection of medication is based primarily upon side effects and toxicities, as well as differences in the amount of clinical experience with use of each drug for CVS within each age group. (See <a class="local">'Prophylactic medications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children &lt;5 years, we suggest prophylactic treatment with <a class="drug drug_general" data-topicid="9311" href="/d/drug information/9311.html" rel="external">cyproheptadine</a> or <a class="drug drug_general" data-topicid="10091" href="/d/drug information/10091.html" rel="external">pizotifen</a> rather than other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This preference is based primarily on a more favorable side effect profile in younger children and is supported by an expert panel. Potential side effects of cyproheptadine include weight gain and sedation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children ≥5 years and adults, we (and an expert panel) suggest <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> or other tricyclic antidepressant (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This preference is based upon the greater clinical experience with amitriptyline for CVS compared with alternative agents (<a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a>, <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>) and overall higher level of effectiveness, despite frequent but tolerable side effects.</p><p></p><p class="bulletIndent1">Alternatives include <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a>, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> (typically used only for children), or selected anticonvulsants. Dosing, side effects, and alternatives are outlined in the table  (<a class="graphic graphic_table graphicRef68579" href="/d/graphic/68579.html" rel="external">table 4C</a>). In addition, for most children who warrant prophylaxis, we suggest a trial of concomitant treatment with coenzyme Q10, with or without L-carnitine and <a class="drug drug_general" data-topicid="9861" href="/d/drug information/9861.html" rel="external">riboflavin</a> supplementation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Coenzyme Q10, sometimes with riboflavin, is sometimes used as an adjunct to other prophylactic agents in adults, based upon indirect and limited evidence for efficacy in prophylaxis of migraines. (See <a class="local">'Children and adolescents'</a> above and <a class="local">'Adults'</a> above.)</p><p></p><p class="headingAnchor" id="H1074400964"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Emily Dulude, MD, Richard G Boles, MD, and David J Desilets, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Li BU, Balint JP. Cyclic vomiting syndrome: evolution in our understanding of a brain-gut disorder. Adv Pediatr 2000; 47:117.</a></li><li><a class="nounderline abstract_t">Kumar N, Bashar Q, Reddy N, et al. Cyclic Vomiting Syndrome (CVS): is there a difference based on onset of symptoms--pediatric versus adult? BMC Gastroenterol 2012; 12:52.</a></li><li><a class="nounderline abstract_t">Abell TL, Kim CH, Malagelada JR. Idiopathic cyclic nausea and vomiting--a disorder of gastrointestinal motility? Mayo Clin Proc 1988; 63:1169.</a></li><li><a class="nounderline abstract_t">Fleisher DR, Gornowicz B, Adams K, et al. Cyclic Vomiting Syndrome in 41 adults: the illness, the patients, and problems of management. BMC Med 2005; 3:20.</a></li><li><a class="nounderline abstract_t">Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal Disorders. Gastroenterology 2016; 150:1380.</a></li><li><a class="nounderline abstract_t">Hyams JS, Di Lorenzo C, Saps M, et al. Functional Disorders: Children and Adolescents. Gastroenterology 2016.</a></li><li><a class="nounderline abstract_t">Lombard HC. Evrose de la digestion, caracteriseo par des crises periodiques de vomissements et une profonde modification de l’assimilation. Gazette Medicale de Paris 1861; 6:312.</a></li><li><a class="nounderline abstract_t">Gee S. On fitful or recurrent vomiting. St Bartholomew Hospital Reports 1882; 18:1.</a></li><li><a class="nounderline abstract_t">Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379.</a></li><li><a class="nounderline abstract_t">Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. Neurogastroenterol Motil 2019; 31 Suppl 2:e13604.</a></li><li><a class="nounderline abstract_t">Abu-Arafeh I, Russell G. Cyclical vomiting syndrome in children: a population-based study. J Pediatr Gastroenterol Nutr 1995; 21:454.</a></li><li><a class="nounderline abstract_t">CULLEN KJ, MA CDONALD WB. The periodic syndrome: its nature and prevalence. Med J Aust 1963; 50(2):167.</a></li><li><a class="nounderline abstract_t">Fitzpatrick E, Bourke B, Drumm B, Rowland M. The incidence of cyclic vomiting syndrome in children: population-based study. Am J Gastroenterol 2008; 103:991.</a></li><li><a class="nounderline abstract_t">Lucarelli S, Corrado G, Pelliccia A, et al. Cyclic vomiting syndrome and food allergy/intolerance in seven children: a possible association. Eur J Pediatr 2000; 159:360.</a></li><li><a class="nounderline abstract_t">Prakash C, Staiano A, Rothbaum RJ, Clouse RE. Similarities in cyclic vomiting syndrome across age groups. Am J Gastroenterol 2001; 96:684.</a></li><li><a class="nounderline abstract_t">Withers GD, Silburn SR, Forbes DA. Precipitants and aetiology of cyclic vomiting syndrome. Acta Paediatr 1998; 87:272.</a></li><li><a class="nounderline abstract_t">HOYT CS, STICKLER GB. A study of 44 children with the syndrome of recurrent (cyclic) vomiting. Pediatrics 1960; 25:775.</a></li><li><a class="nounderline abstract_t">Lee WS, Kaur P, Boey CC, Chan KC. Cyclic vomiting syndrome in South-East Asian children. J Paediatr Child Health 1998; 34:568.</a></li><li><a class="nounderline abstract_t">Li BU, Murray RD, Heitlinger LA, et al. Is cyclic vomiting syndrome related to migraine? J Pediatr 1999; 134:567.</a></li><li><a class="nounderline abstract_t">Haan J, Kors EE, Ferrari MD. Familial cyclic vomiting syndrome. Cephalalgia 2002; 22:552.</a></li><li><a class="nounderline abstract_t">Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology 2021; 160:99.</a></li><li><a class="nounderline abstract_t">Sagar RC, Sood R, Gracie DJ, et al. Cyclic vomiting syndrome is a prevalent and under-recognized condition in the gastroenterology outpatient clinic. Neurogastroenterol Motil 2018; 30.</a></li><li><a class="nounderline abstract_t">Aziz I, Palsson OS, Whitehead WE, et al. Epidemiology, Clinical Characteristics, and Associations for Rome IV Functional Nausea and Vomiting Disorders in Adults. Clin Gastroenterol Hepatol 2019; 17:878.</a></li><li><a class="nounderline abstract_t">Venkatesan T, Prieto T, Barboi A, et al. Autonomic nerve function in adults with cyclic vomiting syndrome: a prospective study. Neurogastroenterol Motil 2010; 22:1303.</a></li><li><a class="nounderline abstract_t">Prakash C, Clouse RE. Cyclic vomiting syndrome in adults: clinical features and response to tricyclic antidepressants. Am J Gastroenterol 1999; 94:2855.</a></li><li><a class="nounderline abstract_t">Levinthal DJ. The Cyclic Vomiting Syndrome Threshold: A Framework for Understanding Pathogenesis and Predicting Successful Treatments. Clin Transl Gastroenterol 2016; 7:e198.</a></li><li><a class="nounderline abstract_t">Welch KM. Scientific basis of migraine: speculation on the relationship to cyclic vomiting. Dig Dis Sci 1999; 44:26S.</a></li><li><a class="nounderline abstract_t">Jernigan SA, Ware LM. Reversible quantitative EEG changes in a case of cyclic vomiting: evidence for migraine equivalent. Dev Med Child Neurol 1991; 33:80.</a></li><li><a class="nounderline abstract_t">To J, Issenman RM, Kamath MV. Evaluation of neurocardiac signals in pediatric patients with cyclic vomiting syndrome through power spectral analysis of heart rate variability. J Pediatr 1999; 135:363.</a></li><li><a class="nounderline abstract_t">Chelimsky TC, Chelimsky GG. Autonomic abnormalities in cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2007; 44:326.</a></li><li><a class="nounderline abstract_t">Boles RG, Chun N, Senadheera D, Wong LJ. Cyclic vomiting syndrome and mitochondrial DNA mutations. Lancet 1997; 350:1299.</a></li><li><a class="nounderline abstract_t">Boles RG, Adams K, Li BU. Maternal inheritance in cyclic vomiting syndrome. Am J Med Genet A 2005; 133A:71.</a></li><li><a class="nounderline abstract_t">Boles RG, Zaki EA, Lavenbarg T, et al. Are pediatric and adult-onset cyclic vomiting syndrome (CVS) biologically different conditions? Relationship of adult-onset CVS with the migraine and pediatric CVS-associated common mtDNA polymorphisms 16519T and 3010A. Neurogastroenterol Motil 2009; 21:936.</a></li><li><a class="nounderline abstract_t">Boles RG, Lovett-Barr MR, Preston A, et al. Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study. BMC Neurol 2010; 10:10.</a></li><li><a class="nounderline abstract_t">Boles RG. High degree of efficacy in the treatment of cyclic vomiting syndrome with combined co-enzyme Q10, L-carnitine and amitriptyline, a case series. BMC Neurol 2011; 11:102.</a></li><li><a class="nounderline abstract_t">Van Calcar SC, Harding CO, Wolff JA. L-carnitine administration reduces number of episodes in cyclic vomiting syndrome. Clin Pediatr (Phila) 2002; 41:171.</a></li><li><a class="nounderline abstract_t">Zaki EA, Freilinger T, Klopstock T, et al. Two common mitochondrial DNA polymorphisms are highly associated with migraine headache and cyclic vomiting syndrome. Cephalalgia 2009; 29:719.</a></li><li><a class="nounderline abstract_t">Lee J, Wong SA, Li BU, Boles RG. NextGen nuclear DNA sequencing in cyclic vomiting syndrome reveals a significant association with the stress-induced calcium channel (RYR2). Neurogastroenterol Motil 2015; 27:990.</a></li><li><a class="nounderline abstract_t">Duquesnoy C, Mamet JP, Sumner D, Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 1998; 6:99.</a></li><li><a class="nounderline abstract_t">Scobie BA. Recurrent vomiting in adults. A syndrome? Med J Aust 1983; 1:329.</a></li><li><a class="nounderline abstract_t">Hikita T, Kodama H, Kaneko S, et al. Sumatriptan as a treatment for cyclic vomiting syndrome: a clinical trial. Cephalalgia 2011; 31:504.</a></li><li><a class="nounderline abstract_t">Sato T, Igarashi N, Minami S, et al. Recurrent attacks of vomiting, hypertension and psychotic depression: a syndrome of periodic catecholamine and prostaglandin discharge. Acta Endocrinol (Copenh) 1988; 117:189.</a></li><li><a class="nounderline abstract_t">Taché Y. Cyclic vomiting syndrome: the corticotropin-releasing-factor hypothesis. Dig Dis Sci 1999; 44:79S.</a></li><li><a class="nounderline abstract_t">Hejazi RA, Lavenbarg TH, Pasnoor M, et al. Autonomic nerve function in adult patients with cyclic vomiting syndrome. Neurogastroenterol Motil 2011; 23:439.</a></li><li><a class="nounderline abstract_t">Cooper CJ, Said S, Bizet J, et al. Rapid or normal gastric emptying as new supportive criteria for diagnosing cyclic vomiting syndrome in adults. Med Sci Monit 2014; 20:1491.</a></li><li><a class="nounderline abstract_t">Turchetti A, Guglielmi S, Fossati C, et al. Gastric emptying time in cyclic vomiting syndrome in children. Eur Rev Med Pharmacol Sci 2004; 8:295.</a></li><li><a class="nounderline abstract_t">Bahji A, Brothers TD, Danilewitz M. Considering Cannabis Use in Differential Diagnosis: A Teachable Moment. JAMA Intern Med 2022; 182:66.</a></li><li><a class="nounderline abstract_t">Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut 2004; 53:1566.</a></li><li><a class="nounderline abstract_t">Sontineni SP, Chaudhary S, Sontineni V, Lanspa SJ. Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse. World J Gastroenterol 2009; 15:1264.</a></li><li><a class="nounderline abstract_t">Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc 2012; 87:114.</a></li><li><a class="nounderline abstract_t">Sorensen CJ, DeSanto K, Borgelt L, et al. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review. J Med Toxicol 2017; 13:71.</a></li><li><a class="nounderline abstract_t">Lapoint J, Meyer S, Yu CK, et al. Cannabinoid Hyperemesis Syndrome: Public Health Implications and a Novel Model Treatment Guideline. West J Emerg Med 2018; 19:380.</a></li><li><a class="nounderline abstract_t">Choung RS, Locke GR 3rd, Lee RM, et al. Cyclic vomiting syndrome and functional vomiting in adults: association with cannabinoid use in males. Neurogastroenterol Motil 2012; 24:20.</a></li><li><a class="nounderline abstract_t">Venkatesan T, Levinthal DJ, Li BUK, et al. Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome. Neurogastroenterol Motil 2019; 31 Suppl 2:e13606.</a></li><li><a class="nounderline abstract_t">Blumentrath CG, Dohrmann B, Ewald N. Cannabinoid hyperemesis and the cyclic vomiting syndrome in adults: recognition, diagnosis, acute and long-term treatment. Ger Med Sci 2017; 15:Doc06.</a></li><li><a class="nounderline abstract_t">Fleisher DR, Matar M. The cyclic vomiting syndrome: a report of 71 cases and literature review. J Pediatr Gastroenterol Nutr 1993; 17:361.</a></li><li><a class="nounderline abstract_t">Marcus DA, Scharff L, Turk D, Gourley LM. A double-blind provocative study of chocolate as a trigger of headache. Cephalalgia 1997; 17:855.</a></li><li><a class="nounderline abstract_t">Li BU, Issenman RM, Sarna SK. Consensus statement--2nd International Scientific Symposium on CVS. The Faculty of The 2nd International Scientific Symposium on Cyclic Vomiting Syndrome. Dig Dis Sci 1999; 44:9S.</a></li><li><a class="nounderline abstract_t">Tarbell SE, Li BU. Anxiety Measures Predict Health-Related Quality of Life in Children and Adolescents with Cyclic Vomiting Syndrome. J Pediatr 2015; 167:633.</a></li><li><a class="nounderline abstract_t">Li BUK. Managing cyclic vomiting syndrome in children: beyond the guidelines. Eur J Pediatr 2018; 177:1435.</a></li><li><a class="nounderline abstract_t">Kovacic K, Miranda A, Chelimsky G, et al. Chronic idiopathic nausea of childhood. J Pediatr 2014; 164:1104.</a></li><li><a class="nounderline abstract_t">Pareek N, Fleisher DR, Abell T. Cyclic vomiting syndrome: what a gastroenterologist needs to know. Am J Gastroenterol 2007; 102:2832.</a></li><li><a class="nounderline abstract_t">Parkman HP, Yates K, Hasler WL, et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology 2011; 140:101.</a></li><li><a class="nounderline abstract_t">Hikita T, Kodama H, Ogita K, et al. Cyclic Vomiting Syndrome in Infants and Children: A Clinical Follow-Up Study. Pediatr Neurol 2016; 57:29.</a></li><li><a class="nounderline abstract_t">Symon DN, Russell G. Abdominal migraine: a childhood syndrome defined. Cephalalgia 1986; 6:223.</a></li><li><a class="nounderline abstract_t">Fitzpatrick E, Bourke B, Drumm B, Rowland M. Outcome for children with cyclical vomiting syndrome. Arch Dis Child 2007; 92:1001.</a></li><li><a class="nounderline abstract_t">Benninga MA, Faure C, Hyman PE, et al. Childhood Functional Gastrointestinal Disorders: Neonate/Toddler. Gastroenterology 2016.</a></li><li><a class="nounderline abstract_t">Olson AD, Li BU. The diagnostic evaluation of children with cyclic vomiting: a cost-effectiveness assessment. J Pediatr 2002; 141:724.</a></li><li><a class="nounderline abstract_t">Lucia-Casadonte CJ, Whaley KG, Chogle AS. Yield and Costs of Evaluating Children With Cyclic Vomiting Syndrome. J Pediatr Gastroenterol Nutr 2018; 67:13.</a></li><li><a class="nounderline abstract_t">Li BU, Murray RD, Heitlinger LA, et al. Heterogeneity of diagnoses presenting as cyclic vomiting. Pediatrics 1998; 102:583.</a></li><li><a class="nounderline abstract_t">Schulte-Bockholt A, Kugathasan S, Mesrobian HG, Werlin SL. Ureteropelvic junction obstruction: an overlooked cause of cyclic vomiting. Am J Gastroenterol 2002; 97:1043.</a></li><li><a class="nounderline abstract_t">Carbonari G, Tonti G, Di Pisa V, et al. Pediatric epilepsies misdiagnosed as gastrointestinal disorders. Epilepsy Behav 2018; 83:137.</a></li><li><a class="nounderline abstract_t">Lee LY, Abbott L, Mahlangu B, et al. The management of cyclic vomiting syndrome:  a systematic review. Eur J Gastroenterol Hepatol 2012; 24:1001.</a></li><li><a class="nounderline abstract_t">Tarbell S, Li BU. Psychiatric symptoms in children and adolescents with cyclic vomiting syndrome and their parents. Headache 2008; 48:259.</a></li><li><a class="nounderline abstract_t">Levinthal DJ, Romutis S, Rajalaban A, et al. Greater intolerance to uncertainty predicts poorer quality of life in adults with cyclic vomiting syndrome. Neurogastroenterol Motil 2021; 33:e14159.</a></li><li><a class="nounderline abstract_t">Reeves PT, Kovacic K, Rogers PL, et al. Development and Assessment of a Low Literacy, Pictographic Cyclic Vomiting Syndrome Action Plan. J Pediatr 2022; 242:174.</a></li><li><a class="nounderline abstract_t">Abdulkader ZM, Bali N, Vaz K, et al. Predictors of Hospital Admission for Pediatric Cyclic Vomiting Syndrome. J Pediatr 2021; 232:154.</a></li><li><a class="nounderline abstract_t">Gui S, Patel N, Issenman R, Kam AJ. Acute Management of Pediatric Cyclic Vomiting Syndrome: A Systematic Review. J Pediatr 2019; 214:158.</a></li><li><a class="nounderline abstract_t">Boles RG, Adams K, Ito M, Li BU. Maternal inheritance in cyclic vomiting syndrome with neuromuscular disease. Am J Med Genet A 2003; 120A:474.</a></li><li class="breakAll">Health Canada. Zofran (ondansetron) - Dosage and Administration of Intravenous Ondansetron in Geriatrics (&gt;65 years of age) - For Health Professionals. 2014. Available at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/39943a-eng.php (Accessed on June 16, 2014).</li><li><a class="nounderline abstract_t">Timaeus S, Elder J, Franco K. Evaluation of the Use of Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients. J Pediatr Hematol Oncol 2018; 40:527.</a></li><li><a class="nounderline abstract_t">Khasawinah TA, Ramirez A, Berkenbosch JW, Tobias JD. Preliminary experience with dexmedetomidine in the treatment of cyclic vomiting syndrome. Am J Ther 2003; 10:303.</a></li><li><a class="nounderline abstract_t">Pasricha PJ, Schuster MM, Saudek CD, et al. Cyclic vomiting: association with multiple homeostatic abnormalities and response to ketorolac. Am J Gastroenterol 1996; 91:2228.</a></li><li><a class="nounderline abstract_t">Bhandari S, Venkatesan T. Novel Treatments for Cyclic Vomiting Syndrome: Beyond Ondansetron and Amitriptyline. Curr Treat Options Gastroenterol 2016; 14:495.</a></li><li><a class="nounderline abstract_t">Cristofori F, Thapar N, Saliakellis E, et al. Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome. Aliment Pharmacol Ther 2014; 40:309.</a></li><li><a class="nounderline abstract_t">Andersen JM, Sugerman KS, Lockhart JR, Weinberg WA. Effective prophylactic therapy for cyclic vomiting syndrome in children using amitriptyline or cyproheptadine. Pediatrics 1997; 100:977.</a></li><li><a class="nounderline abstract_t">Sezer OB, Sezer T. A New Approach to the Prophylaxis of Cyclic Vomiting: Topiramate. J Neurogastroenterol Motil 2016; 22:656.</a></li><li><a class="nounderline abstract_t">Martinez-Esteve Melnikova A, Schäppi MG, Korff C. Riboflavin in cyclic vomiting syndrome: efficacy in three children. Eur J Pediatr 2016; 175:131.</a></li><li><a class="nounderline abstract_t">Worawattanakul M, Rhoads JM, Lichtman SN, Ulshen MH. Abdominal migraine: prophylactic treatment and follow-up. J Pediatr Gastroenterol Nutr 1999; 28:37.</a></li><li><a class="nounderline abstract_t">Badihian N, Saneian H, Badihian S, Yaghini O. Prophylactic Therapy of Cyclic Vomiting Syndrome in Children: Comparison of Amitriptyline and Cyproheptadine: A Randomized Clinical Trial. Am J Gastroenterol 2018; 113:135.</a></li><li><a class="nounderline abstract_t">Symon DN, Russell G. Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine. Arch Dis Child 1995; 72:48.</a></li><li><a class="nounderline abstract_t">Hejazi RA, Reddymasu SC, Namin F, et al. Efficacy of tricyclic antidepressant therapy in adults with cyclic vomiting syndrome: a two-year follow-up study. J Clin Gastroenterol 2010; 44:18.</a></li><li><a class="nounderline abstract_t">Gokhale R, Huttenlocher PR, Brady L, Kirschner BS. Use of barbiturates in the treatment of cyclic vomiting during childhood. J Pediatr Gastroenterol Nutr 1997; 25:64.</a></li><li><a class="nounderline abstract_t">Coskun M, Alyanak B. Psychiatric Co-morbidity and Efficacy of Mirtazapine Treatment in Young Subjects With Chronic or Cyclic Vomiting Syndromes: A Case Series. J Neurogastroenterol Motil 2011; 17:305.</a></li><li><a class="nounderline abstract_t">Shearer J, Luthra P, Ford AC. Cyclic vomiting syndrome: a case series and review of the literature. Frontline Gastroenterol 2018; 9:2.</a></li><li><a class="nounderline abstract_t">Clouse RE, Sayuk GS, Lustman PJ, Prakash C. Zonisamide or levetiracetam for adults with cyclic vomiting syndrome: a case series. Clin Gastroenterol Hepatol 2007; 5:44.</a></li><li><a class="nounderline abstract_t">Mooers H, Srivastava S, Garacci E, Venkatesan T. Retrospective review of patients treated for cyclic vomiting syndrome with topiramate. Aliment Pharmacol Ther 2021; 54:153.</a></li><li><a class="nounderline abstract_t">Cirulli ET, Urban TJ, Marino SE, et al. Genetic and environmental correlates of topiramate-induced cognitive impairment. Epilepsia 2012; 53:e5.</a></li><li><a class="nounderline abstract_t">Loring DW, Williamson DJ, Meador KJ, et al. Topiramate dose effects on cognition: a randomized double-blind study. Neurology 2011; 76:131.</a></li><li><a class="nounderline abstract_t">Boyle CA. Management of menstrual migraine. Neurology 1999; 53:S14.</a></li><li><a class="nounderline abstract_t">Gutgesell H, Atkins D, Barst R, et al. AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry 1999; 38:1047.</a></li><li><a class="nounderline abstract_t">Haghighat M, Dehghani SM, Shahramian I, et al. Combination of erythromycin and propranolol for treatment of childhood cyclic vomiting syndrome: a novel regimen. Gastroenterol Hepatol Bed Bench 2015; 8:270.</a></li></ol></div><div id="topicVersionRevision">Topic 2588 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10959442" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cyclic vomiting syndrome: evolution in our understanding of a brain-gut disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22639867" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cyclic Vomiting Syndrome (CVS): is there a difference based on onset of symptoms--pediatric versus adult?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3199884" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Idiopathic cyclic nausea and vomiting--a disorder of gastrointestinal motility?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16368014" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cyclic Vomiting Syndrome in 41 adults: the illness, the patients, and problems of management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27147122" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gastroduodenal Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27144632" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Functional Disorders: Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evrose de la digestion, caracteriseo par des crises periodiques de vomissements et une profonde modification de l’assimilation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : On fitful or recurrent vomiting</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18728540" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31241819" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8583299" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cyclical vomiting syndrome in children: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14024194" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The periodic syndrome: its nature and prevalence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18070235" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The incidence of cyclic vomiting syndrome in children: population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10834522" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cyclic vomiting syndrome and food allergy/intolerance in seven children: a possible association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11280534" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Similarities in cyclic vomiting syndrome across age groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9560033" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Precipitants and aetiology of cyclic vomiting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14403528" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A study of 44 children with the syndrome of recurrent (cyclic) vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9928652" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cyclic vomiting syndrome in South-East Asian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228291" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Is cyclic vomiting syndrome related to migraine?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12230597" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Familial cyclic vomiting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32294476" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28745840" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cyclic vomiting syndrome is a prevalent and under-recognized condition in the gastroenterology outpatient clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29857155" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Epidemiology, Clinical Characteristics, and Associations for Rome IV Functional Nausea and Vomiting Disorders in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20667005" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Autonomic nerve function in adults with cyclic vomiting syndrome: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10520833" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cyclic vomiting syndrome in adults: clinical features and response to tricyclic antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27787513" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The Cyclic Vomiting Syndrome Threshold: A Framework for Understanding Pathogenesis and Predicting Successful Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10490036" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Scientific basis of migraine: speculation on the relationship to cyclic vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1995411" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Reversible quantitative EEG changes in a case of cyclic vomiting: evidence for migraine equivalent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10484804" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Evaluation of neurocardiac signals in pediatric patients with cyclic vomiting syndrome through power spectral analysis of heart rate variability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17325552" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Autonomic abnormalities in cyclic vomiting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9357417" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cyclic vomiting syndrome and mitochondrial DNA mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15643622" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Maternal inheritance in cyclic vomiting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19368653" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Are pediatric and adult-onset cyclic vomiting syndrome (CVS) biologically different conditions? Relationship of adult-onset CVS with the migraine and pediatric CVS-associated common mtDNA polymorphisms 16519T and 3010A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20109231" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21846334" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : High degree of efficacy in the treatment of cyclic vomiting syndrome with combined co-enzyme Q10, L-carnitine and amitriptyline, a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11999680" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : L-carnitine administration reduces number of episodes in cyclic vomiting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19220304" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Two common mitochondrial DNA polymorphisms are highly associated with migraine headache and cyclic vomiting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25925909" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : NextGen nuclear DNA sequencing in cyclic vomiting syndrome reveals a significant association with the stress-induced calcium channel (RYR2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9795022" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6835134" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Recurrent vomiting in adults. A syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21147834" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sumatriptan as a treatment for cyclic vomiting syndrome: a clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2837885" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Recurrent attacks of vomiting, hypertension and psychotic depression: a syndrome of periodic catecholamine and prostaglandin discharge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10490044" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cyclic vomiting syndrome: the corticotropin-releasing-factor hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21323793" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Autonomic nerve function in adult patients with cyclic vomiting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25145650" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Rapid or normal gastric emptying as new supportive criteria for diagnosing cyclic vomiting syndrome in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15745390" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Gastric emptying time in cyclic vomiting syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34842899" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Considering Cannabis Use in Differential Diagnosis: A Teachable Moment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15479672" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19291829" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22305024" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cannabinoid hyperemesis: a case series of 98 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28000146" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29560069" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cannabinoid Hyperemesis Syndrome: Public Health Implications and a Novel Model Treatment Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21951771" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cyclic vomiting syndrome and functional vomiting in adults: association with cannabinoid use in males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31241817" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28400711" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cannabinoid hyperemesis and the cyclic vomiting syndrome in adults: recognition, diagnosis, acute and long-term treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8145089" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The cyclic vomiting syndrome: a report of 71 cases and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9453274" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A double-blind provocative study of chocolate as a trigger of headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10490032" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Consensus statement--2nd International Scientific Symposium on CVS. The Faculty of The 2nd International Scientific Symposium on Cyclic Vomiting Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26095286" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Anxiety Measures Predict Health-Related Quality of Life in Children and Adolescents with Cyclic Vomiting Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30076469" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Managing cyclic vomiting syndrome in children: beyond the guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24607239" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Chronic idiopathic nausea of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18042112" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cyclic vomiting syndrome: what a gastroenterologist needs to know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20965184" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26861170" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cyclic Vomiting Syndrome in Infants and Children: A Clinical Follow-Up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3802189" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Abdominal migraine: a childhood syndrome defined.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17588965" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Outcome for children with cyclical vomiting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27144631" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Childhood Functional Gastrointestinal Disorders: Neonate/Toddler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12410206" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The diagnostic evaluation of children with cyclic vomiting: a cost-effectiveness assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29373437" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Yield and Costs of Evaluating Children With Cyclic Vomiting Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738180" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Heterogeneity of diagnoses presenting as cyclic vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12003386" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Ureteropelvic junction obstruction: an overlooked cause of cyclic vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29705623" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pediatric epilepsies misdiagnosed as gastrointestinal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22634989" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The management of cyclic vomiting syndrome:  a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18081819" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Psychiatric symptoms in children and adolescents with cyclic vomiting syndrome and their parents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33830558" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Greater intolerance to uncertainty predicts poorer quality of life in adults with cyclic vomiting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34740589" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Development and Assessment of a Low Literacy, Pictographic Cyclic Vomiting Syndrome Action Plan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33259858" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Predictors of Hospital Admission for Pediatric Cyclic Vomiting Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31540764" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Acute Management of Pediatric Cyclic Vomiting Syndrome: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12884425" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Maternal inheritance in cyclic vomiting syndrome with neuromuscular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12884425" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Maternal inheritance in cyclic vomiting syndrome with neuromuscular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29794645" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Evaluation of the Use of Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12845396" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Preliminary experience with dexmedetomidine in the treatment of cyclic vomiting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8855755" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cyclic vomiting: association with multiple homeostatic abnormalities and response to ketorolac.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27757817" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Novel Treatments for Cyclic Vomiting Syndrome: Beyond Ondansetron and Amitriptyline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24898244" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9374568" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effective prophylactic therapy for cyclic vomiting syndrome in children using amitriptyline or cyproheptadine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27302967" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A New Approach to the Prophylaxis of Cyclic Vomiting: Topiramate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26226892" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Riboflavin in cyclic vomiting syndrome: efficacy in three children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9890466" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Abdominal migraine: prophylactic treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28719594" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prophylactic Therapy of Cyclic Vomiting Syndrome in Children: Comparison of Amitriptyline and Cyproheptadine: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7717738" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20027010" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Efficacy of tricyclic antidepressant therapy in adults with cyclic vomiting syndrome: a two-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9226529" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Use of barbiturates in the treatment of cyclic vomiting during childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21860824" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Psychiatric Co-morbidity and Efficacy of Mirtazapine Treatment in Young Subjects With Chronic or Cyclic Vomiting Syndromes: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29484154" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Cyclic vomiting syndrome: a case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17157078" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Zonisamide or levetiracetam for adults with cyclic vomiting syndrome: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34114666" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Retrospective review of patients treated for cyclic vomiting syndrome with topiramate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22091778" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Genetic and environmental correlates of topiramate-induced cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21148119" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Topiramate dose effects on cognition: a randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10487508" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Management of menstrual migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10434498" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26468347" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Combination of erythromycin and propranolol for treatment of childhood cyclic vomiting syndrome: a novel regimen.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
